Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL

Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL

BackgroundAnaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) is a rare, mature T-cell non-Hodgkin lymphoma. The prognosis of patients with relapsed or refractory ALCL following first-line chemotherapy is extremely poor. NCCN guidelines recommend intensified chemotherapy w...

Full description

Bibliographic Details
Main Authors: Wanying Liu, Jiaying Wu, Xi Ming, Qi Zhang, Delian Zhou, Rubing Zheng, Mi Zhou, Zhen Shang, Liting Chen, Xiaojian Zhu, Yi Xiao
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Immunology
Subjects:
anaplastic large cell lymphoma
T-cell non-Hodgkin lymphoma
crizotinib
CAR T cell therapy
autologous stem cell transplantation
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1346001/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1346001/full

Similar Items